A comparison of neuroprotective efficacy of two novel reactivators of acetylcholinesterase called K920 and K923 with the oxime K203 and trimedoxime in tabun-poisoned rats

References

• Bajgar J. (2004). Organophosphate/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem 38:151–216.
   PubMed Web of Science ®Google Scholar
• Berend S, Vrdoljak AL, Radic B, Kuca K. (2008). New bispyridinium oximes: in vitro and in vivo evaluation of their biological efficiency in soman and tabun poisoning. Chem Biol Interact 175:413–6.
   PubMed Web of Science ®Google Scholar
• Cabal J, Bajgar J. (1999). Tabun – reappearance 50 years later (in Czech). Chem Listy 93:27–31.
   Web of Science ®Google Scholar
• Cabal J, Kuca K, Kassa J. (2004). Specification of the structure of oximes able to reactivate tabun-inhibited acetylcholinesterase. Basic Clin Pharmacol Toxicol 95:81–6.
   PubMed Web of Science ®Google Scholar
• Chen Y. (2012). Organophosphate-induced brain damage: mechanisms, neuropsychiatric and neurological consequences, and potential therapeutic strategies. NeuroToxicology 33:391–400.
   PubMed Web of Science ®Google Scholar
• Colovic MB, Krstic DZ, Lazarevic-Pasti TD, et al. (2013). Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 11:315–35.
   PubMed Web of Science ®Google Scholar
• de Jong LPA, Benschop HP, van den Berg GR, et al. (1981). Reactivation of tabun-inhibited acetylcholinesterase by 1-(hetero)arylmethyl-pyridinium oximes. Eur J Med Chem 16:257–62.
   Web of Science ®Google Scholar
• Delfino RT, Ribeiro TS, Figueroa-Villar JD. (2009). Organophosphorus compounds as chemical warfare agents: a review. J Braz Chem Soc 20:407–28.
   Web of Science ®Google Scholar
• Ekström F, Akfur C, Tunemalm AK, Lundberg S. (2006). Structural changes of phenylalanine 338 and histidine 447 revealed by the crystal structures of tabun-inhibited murine acetylcholinesterase. Biochemistry 45:74–81.
   PubMed Web of Science ®Google Scholar
• Frantik E, Hornychova M. (1995). Clustering of neurobehavioral measures of toxicity. Homeostasis 36:19–25.
   Google Scholar
• Hoffman A, Eisenkraft A, Finkelstein A, et al. (2007). A decade after the Tokyo sarin attack: a review of neurological follow-up of the victims. Mil Med 172:607–10.
   PubMed Web of Science ®Google Scholar
• Jokanovic M. (2012). Structure-activity relationship and efficacy of pyridinium oximes in the treatment of poisoning with organophosphorus compounds: a review of recent data. Curr Topic Med Chem 12:1775–89.
   PubMed Web of Science ®Google Scholar
• Jun D, Kuca K, Stodulka P, et al. (2007). HPLC analysis of HI-6 dichloride and dimethanesulfonate – antidotes against nerve agents and organophosphorus pesticides. Anal Lett 40:2783–7.
   Google Scholar
• Kalasz H, Nurulain SM, Veress G, et al. (2015). Mini review on blood-brain barrier penetration of pyridinium aldoximes. J Appl Toxicol 35:116–23.
   PubMed Web of Science ®Google Scholar
• Kassa J, Karasova J, Bajgar J, et al. (2009B). A comparison of the reactivating and therapeutic efficacy of newly developed bispyridinium oximes (K250, K251) with commonly used oximes against tabun in rats and mice. J Enzym Inhib Med Chem 24:1040–4.
   PubMed Web of Science ®Google Scholar
• Kassa J, Karasova J, Musilek K, Kuca K. (2008). An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) with commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice. Toxicology 243:311–6.
   PubMed Web of Science ®Google Scholar
• Kassa J, Karasova J, Vasina L, et al. (2009). A comparison of neuroprotective efficacy of newly developed oximes (K203, K206) and commonly used oximes (obidoxime, HI-6) in tabun-poisoned rats. Drug Chem Toxicol 32:128–38.
   PubMed Web of Science ®Google Scholar
• Kassa J, Krejcova G. (2003). Neuroprotective effects of currently used antidotes in tabun-poisoned rats. Pharmacol Toxicol 92:258–64.
   PubMedGoogle Scholar
• Kassa J, Kuca K, Bartosova L, Kunesova G. (2007). The development of new structural analogues of oximes for the antidotal treatment of poisoning by nerve agents and the comparison of their reactivating and therapeutic efficacy with currently available oximes. Curr. Org Chem 11:267–83.
   Google Scholar
• Kassa J, Kunesova G. (2006). Comparison of the neuroprotective effects of the newly developed oximes (K027, K048) with trimedoxime in tabun-poisoned rats. J Appl Biomed 4:123–34.
   Google Scholar
• Kassa J, Sepsova V, Horova A, Musilek K. (2015a). The comparison of the reactivating and therapeutic efficacy of two novel bispyridinium oximes (K920, K923) with the oxime K203 and trimedoxime in tabun-poisoned rats and mice. J Appl Biomed 13:299–304.
   Web of Science ®Google Scholar
• Kassa J, Misik J, Zdarova Karasova J. (2015b). Neuroprotective efficacy of newly developed oximes in comparison with currently available oximes in tabun-poisoned rats. J Appl Biomed 13:39–46.
   Web of Science ®Google Scholar
• Kassa J, Sepsova V, Tumova M, et al. (2014). The evaluation of the reactivating and therapeutic efficacy of two novel oximes (K361, K378) in comparison with the oxime K203 and trimedoxime in tabun-poisoned rats and mice. Toxicol Mech Method 24:173–8.
   PubMed Web of Science ®Google Scholar
• Katz FS, Pecic S, Tran TH, et al. (2015). Discovery of new classes of compounds that reactivate acetylcholinesterase inhibited by organophosphates. ChemBioChem 16:2205–15.
   PubMed Web of Science ®Google Scholar
• Kovarik Z, Macek N, Sit RK, et al. (2013). Centrally acting oximes in reactivation of tabun-phosphoramidated AChE. Chem Biol Interact 203:77–80.
   PubMed Web of Science ®Google Scholar
• Kuca K, Jun D, Musilek K. (2006). Structural requirements of acetylcholinesterase reactivators. Mini Rev Med Chem 6:269–77.
   PubMed Web of Science ®Google Scholar
• Lorke DE, Kalasz H, Petroianu GA, Tekes K. (2008). Entry of oximes into the brain: a review. Curr Med Chem 15:743–53.
   PubMed Web of Science ®Google Scholar
• Moser VC, Tilson H, McPhail RC, et al. (1997). The IPCS collaborative study on neurobehavioral screening methods: II. Protocol design and testing procedures. NeuroToxicol 18:929–38.
   PubMed Web of Science ®Google Scholar
• Musilek K, Dolezal M, Gunn-Moore F, Kuca K. (2011). Design, evaluation and structure-activity relationship studies of the AChE reactivators against organophosphorus pesticides. Med Res Rev 31:548–75.
   PubMed Web of Science ®Google Scholar
• Musilek K, Holas O, Kuca K, et al. (2007). Synthesis of the novel series of non-symmetrical bispyridinium compounds bearing xylene linker and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase. J. Enzym Inhib Med Chem 22:425–32.
   PubMed Web of Science ®Google Scholar
• Musilek K, Holas O, Misik J, et al. (2010). Monooxime-monocarbamoyl bispyridinium xylene-linked reactivators of acetylcholinesterase – synthesis, in vitro and toxicity evaluation, and docking studies. ChemMedChem 5:247–54.
   PubMed Web of Science ®Google Scholar
• Musilek K, Kucera J, Jun D, et al. (2008). Monoquaternary pyridinium salts with modified side chain – synthesis and evaluation on model of tabun- and paraoxon-inhibited acetylcholinestrase. Bioorg Med Chem 16:8218–23.
   PubMed Web of Science ®Google Scholar
• Niessen KV, Tattersall JEH, Timperley CM, et al. (2011). Interaction of bispyridinium compounds with the orthosteric binding site of human α7 and Torpedo californica nicotinic acetylcholine receptors (nAChRs). Toxicol Lett 206:100–4.
   PubMed Web of Science ®Google Scholar
• Nurulain SM, Lorke DE, Hasan MY, et al. (2009). Efficacy of eight experimental bispyridinium oximes against paraoxon-induced mortality: comparison with the conventional oximes pralidoxime and obidoxime. Neurotox Res 16:60–7.
   PubMed Web of Science ®Google Scholar
• Ochoa R, Rodriguez CA, Zuluaga AF. (2016). Perspectives for the structure-based design of acetycholinesterase reactivators. J Mol Graph Modell 68:176–83.
   PubMed Web of Science ®Google Scholar
• Sakurada K, Matsubara K, Shimizu K, et al. (2003). Pralidoxime iodide (2-PAM) penetrates across the blood-brain barrier. Neurochem Res 28:1401–7.
   PubMed Web of Science ®Google Scholar
• Sharma R, Gupta B, Singh N, et al. (2015). Development and structural modifications of cholinesterase reactivators against chemical warfare agents in last decade: a review. Mini Rev Med Chem 15:58–72.
   PubMed Web of Science ®Google Scholar
• Sürig U, Gaal K, Kostenis E, et al. (2006). Muscarinic allosteric modulators. Atypical structure-activity-relationships in bispyridinium-type compounds. Arch Pharm Chem Life Sci 339:207–12.
   PubMed Web of Science ®Google Scholar
• Van Helden HPM, Busker RW, Melchers BPC, Bruijnzeel PLB. (1996). Pharmacological effects of oximes: how relevant are they? Arch Toxicol 70:779–86.
   PubMed Web of Science ®Google Scholar
• Voicu V, Bajgar J, Medvedovici A, et al. (2010). Pharmacokinetics and pharmacodynamics of some oximes and associated therapeutic consequences: a critical review. J Appl Toxicol 30:719–29.
   PubMed Web of Science ®Google Scholar
• Voicu V, Radulescu FS, Medvedovici A. (2015). Relationships between the antidotal efficacy and structure, PK/PD parameters and bio-relevant molecular descriptors of AChE reactivating oximes: inclusion and integration to biopharmaceutical classification systems. Expert Opin Drug Metab Toxicol 11:95–109.
   PubMed Web of Science ®Google Scholar
• Wilhelm CM, Snider TH, Babin MC, et al. (2014). A comprehensive evaluation of the efficacy of leading oxime therapies in guinea pigs exposed to organophosphorus chemical warfare agents or pesticides. Toxicol Appl Pharmacol 281:254–65.
   PubMed Web of Science ®Google Scholar
• Worek F, Wille T, Koller M, Thierman H. (2012). Reactivation kinetics of a series of related bispyridinium oximes with organophosphate-inhibited human acetylcholinesterase: structure – activity relationships. Biochem Pharmacol 83:1700–6.
   PubMed Web of Science ®Google Scholar
• Yamasue H, Abe O, Kasai K, et al. (2007). Human brain structural changes related to acute single exposure to sarin. Ann Neurol 61:37–46.
   PubMed Web of Science ®Google Scholar
• Zdarova Karasova J, Stodulka P, Kuca K. (2010). In vitro screening of blood-brain barrier penetration of clinically used acetylcholinesterase reactivators. J Appl Biomed 8:35–40.
   Web of Science ®Google Scholar